Show simple item record

dc.contributor.authorVarlotto, John M.
dc.contributor.authorVeronesi, Giulia
dc.date2022-08-11T08:09:50.000
dc.date.accessioned2022-08-23T16:45:33Z
dc.date.available2022-08-23T16:45:33Z
dc.date.issued2018-06-18
dc.date.submitted2018-08-08
dc.identifier.citation<p>Front Oncol. 2018 Jun 18;8:233. doi: 10.3389/fonc.2018.00233. eCollection 2018. <a href="https://doi.org/10.3389/fonc.2018.00233">Link to article on publisher's site</a></p>
dc.identifier.issn2234-943X (Linking)
dc.identifier.doi10.3389/fonc.2018.00233
dc.identifier.pmid29967762
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40706
dc.description.abstractAt the time we agreed to edit this special edition of Frontiers in early 2017, the immunotherapy revolution was already established in the second-line treatment of metastatic non-small cell lung cancer (NSCLC) and even to a select group of patients (those whose tumor cells expressed PD-L1 of ≥50%) in the first-line treatment of metastatic disease. We felt that the summarization and understanding of the strengths and benefits of our local modalities were needed prior to the possible integration of immunotherapy into the treatment paradigms of Stages I–III NSCLC and small cell lung cancer (SCLC).
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29967762&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright: © 2018 Varlotto and Veronesi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectlung cancer
dc.subjectlung cancer treatment
dc.subjectmulti-modality treatment
dc.subjectradiation therapy
dc.subjectthoracic surgery
dc.subjectNeoplasms
dc.subjectOncology
dc.subjectRespiratory Tract Diseases
dc.subjectTherapeutics
dc.titleEditorial: Controversies in the Local Management of Lung Cancer
dc.typeEditorial
dc.source.journaltitleFrontiers in oncology
dc.source.volume8
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4520&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3509
dc.identifier.contextkey12624490
refterms.dateFOA2022-08-23T16:45:34Z
html.description.abstract<p>At the time we agreed to edit this special edition of Frontiers in early 2017, the immunotherapy revolution was already established in the second-line treatment of metastatic non-small cell lung cancer (NSCLC) and even to a select group of patients (those whose tumor cells expressed PD-L1 of ≥50%) in the first-line treatment of metastatic disease. We felt that the summarization and understanding of the strengths and benefits of our local modalities were needed prior to the possible integration of immunotherapy into the treatment paradigms of Stages I–III NSCLC and small cell lung cancer (SCLC).</p>
dc.identifier.submissionpathoapubs/3509
dc.contributor.departmentDepartment of Radiation Oncology
dc.source.pages233


Files in this item

Thumbnail
Name:
fonc_08_00233.pdf
Size:
117.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright: © 2018 Varlotto and Veronesi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as Copyright: © 2018 Varlotto and Veronesi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.